Potassium

Potassium

SCHEMBL526463

COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1onc(C(=O)O)c1CC2.[K]

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 8/20 0.69
PLK1 P53350 4/20 0.66
CCNA2 P20248 2/20 0.66
CDK2 P24941 2/20 0.66
CCNA1 P78396 2/20 0.66
PLK3 Q9H4B4 2/20 0.66
PLK2 Q9NYY3 2/20 0.66
PIM1 P11309 2/20 0.62
PIM2 Q9P1W9 1/20 0.60
RPS6KA4 O75676 1/20 0.57
CDK1 P06493 1/20 0.57
KIT P10721 1/20 0.57
IMPDH2 P12268 1/20 0.57
CCNB1 P14635 1/20 0.57
CSNK2A2 P19784 1/20 0.57
CCNE1 P24864 1/20 0.57
FLT4 P35916 1/20 0.57
CSNK1D P48730 1/20 0.57
CSNK1E P49674 1/20 0.57
CDK5 Q00535 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL526084 0.99 TTK (0.69) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL526461 0.98 TTK (0.69) TTKPLK1CCNA2CDK2CCNA1
Potassium Ion SCHEMBL526462 0.92 TTK (0.68) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL10092911 0.90 PLK1 (0.67) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL525524 0.89 TTK (0.69) TTKPLK1CCNA2CDK2CCNA1
Potassium SCHEMBL526090 0.89 TTK (0.68) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL525895 0.88 TTK (0.69) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL526088 0.87 TTK (0.68) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL10092906 0.86 TTK (0.92) TTKPLK1CCNA2CDK2CCNA1
SCHEMBL526773 0.85 PLK1 (0.76) TTKPLK1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333205-B2 Isoxazolo-quinazolines as modulators of protein kinase activity NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-05-10 US disclosed
EP-2598508-B1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES SRL (IT) 2015-04-22 EP disclosed
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-06-06 US disclosed
EP-2598508-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY Nerviano Medical Sciences S.r.l. (IT) 2013-06-05 EP disclosed
WO-2012013557-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143896-A1 ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY CSNK1A1, RPS6KA1, CSNK2A1 TTK 341/4885PLK1 183/4885CCNA2 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.